神州细胞: 神州细胞2025年半年度报告摘要

Core Viewpoint - Beijing Sinocell Technology Group Co., Ltd. reported significant declines in revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1]. Financial Summary - Total assets increased by 7.38% to CNY 3,526,218,500.07 compared to the end of the previous year [1]. - Net assets attributable to shareholders decreased by 21.33% to CNY 110,838,929.67 [1]. - Revenue for the period was CNY 972,020,482.48, down 25.50% from CNY 1,304,669,628.08 in the same period last year [1]. - Total profit was reported at a loss of CNY 33,858,151.29, a decline of 126.86% compared to a profit of CNY 126,073,272.07 in the previous year [1]. - Net profit attributable to shareholders was a loss of CNY 33,771,096.29, down 126.87% from CNY 125,705,731.32 [1]. - The net profit after deducting non-recurring gains and losses was a loss of CNY 36,108,173.65, a decrease of 110.61% from CNY 340,264,529.53 [1]. - Net cash flow from operating activities was a negative CNY 206,121,389.52, down 257.03% from CNY 131,265,288.50 [1]. - The weighted average return on net assets was -27.24% [1]. - Basic and diluted earnings per share were both -CNY 0.10, a decrease of 135.71% from CNY 0.28 [1]. - Research and development expenses accounted for 39.91% of revenue, an increase of 3.43 percentage points from 36.48% [1]. Shareholder Information - The total number of shareholders at the end of the reporting period was 9,754 [2]. - The largest shareholder, Nanchang Sinocell Anyuan Enterprise Management Consulting Partnership, held 4.86% of shares, amounting to 21,657,406 shares [2]. - Other notable shareholders included Tianjin Yingya Equity Investment Management Co., Ltd. with 0.84% and Beijing Sinocell Technology Group Co., Ltd. with 0.61% [2][3].